Trials / Recruiting
RecruitingNCT06943677
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsules in Subjects With Advanced Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3019 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3019 capsules.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3019 capsules | TQB3019 capsule is a targeted protein degrader |
Timeline
- Start date
- 2025-05-26
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
- First posted
- 2025-04-24
- Last updated
- 2026-02-12
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06943677. Inclusion in this directory is not an endorsement.